CAT

910.83

+1.65%↑

335.2

+0.88%↑

GEV.US

939.9

+3.99%↑

RTX

183.52

-0.15%↓

219.17

-0.89%↓

CAT

910.83

+1.65%↑

335.2

+0.88%↑

GEV.US

939.9

+3.99%↑

RTX

183.52

-0.15%↓

219.17

-0.89%↓

CAT

910.83

+1.65%↑

335.2

+0.88%↑

GEV.US

939.9

+3.99%↑

RTX

183.52

-0.15%↓

219.17

-0.89%↓

CAT

910.83

+1.65%↑

335.2

+0.88%↑

GEV.US

939.9

+3.99%↑

RTX

183.52

-0.15%↓

219.17

-0.89%↓

CAT

910.83

+1.65%↑

335.2

+0.88%↑

GEV.US

939.9

+3.99%↑

RTX

183.52

-0.15%↓

219.17

-0.89%↓

Inicio・Lista de Acciones・Ocugen Inc

Ocugen Inc

Cerrado

1.21 -1.63

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.2

Máximo

1.21

Métricas clave
By Trading Economics
Ingresos	-1.5M -19M
Ventas	1.7M 1.5M
BPA	-0.06
Margen de beneficios	-1,250.946
Empleados	116
EBITDA	-987K -17M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+699.17% upside

Dividendos
By Acuity
Próximas Ganancias	31 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-193M 433M
Apertura anterior	2.84
Cierre anterior	1.21

Ocugen Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 jun 2026, 23:52 UTC

China's House Price Index YoY release on June 16, 2026, faces cautious market sentiment amid ongoing declines and geopolitical tensions.

13 jun 2026, 23:51 UTC

Correlated Moves

Bitcoin has advanced since Friday, reflecting positive sentiment in the cryptocurrency market. The asset remains below its 20-day moving average and near its one-month range low.

13 jun 2026, 23:41 UTC

U.S. Stocks Surge on SpaceX IPO and Optimism Over U.S.-Iran Peace Talks, While Traders Anticipate Fed's Interest Rate Decision Amid Inflation Concerns.

13 jun 2026, 23:41 UTC

U.S. Stocks Surge on Peace Deal Optimism, Fed Expected to Hold Rates Amid Geopolitical Tensions and Key Economic Data Ahead.

13 jun 2026, 23:41 UTC

U.S. Stocks Surge on Peace Deal Optimism and Global Mineral Economy Shift Ahead of Steady Fed Rate Decision.

13 jun 2026, 23:41 UTC

U.S. Stocks Surge on SpaceX IPO and Peace Deal Hopes, While Investors Brace for Key Economic Data and Fed Rate Decision.

13 jun 2026, 23:41 UTC

Philadelphia Fed Manufacturing Index Release on June 18, 2026, Anticipates Growth Amid Mixed Economic Sentiment and Inflation Concerns.

13 jun 2026, 23:31 UTC

U.S. Industrial Production MoM data for May 2026 expected to rise by 0.2% amid cautious optimism following April's strong performance of 0.7%.

13 jun 2026, 23:21 UTC

U.S. Retail Sales MoM Report on June 17 Expected to Show Modest 0.5% Increase Amid Geopolitical Tensions and Consumer Spending Optimism

13 jun 2026, 23:21 UTC

U.S. Retail Sales Ex Autos Expected to Rise 0.5% in May Amid Cautious Consumer Sentiment and Economic Resilience

13 jun 2026, 23:21 UTC

Canada's New Housing Price Index set for June 17 release, with a forecasted slight decline amid ongoing affordability challenges and government announcements.

13 jun 2026, 23:11 UTC

Market Anticipates U.S. Building Permits Data Release Amid Cautious Optimism and Economic Concerns on June 16, 2026.

13 jun 2026, 23:02 UTC

India's RBI to release monetary policy meeting minutes amid lower-than-expected CPI inflation and rising food costs, influencing future interest rate decisions.

13 jun 2026, 23:02 UTC

Upcoming U.S. Housing Starts Data Release on June 16, 2026 Expected to Reflect Economic Conditions Amid Government Initiatives and Rising Demand.

13 jun 2026, 23:02 UTC

Investors Anticipate Further Increases in U.S. Export Prices Ahead of June 16 Release Amid Geopolitical Developments

13 jun 2026, 23:02 UTC

U.S. Housing Starts Expected to Reach 1.44 Million Units in May Amid Mixed Trends and Policy Discussions Ahead of June 16 Release

13 jun 2026, 23:02 UTC

U.S. Import Prices Report on June 16 Expected to Show 0.9% Increase Amid Geopolitical Optimism and Inflation Concerns

13 jun 2026, 23:02 UTC

Market Anticipates 1.41 Million Building Permits in May 2026 Amidst Cautious Optimism for Housing Sector Recovery.

13 jun 2026, 23:01 UTC

Macro News

DAX 30 Index rises in after-market trading amid optimism for a U.S.-Iran peace deal and President Trump's announcement on the Strait of Hormuz.

13 jun 2026, 22:51 UTC

Japan's Year-on-Year Inflation Rate Release on June 18 Expected to Show Stability Amid Mixed Economic Signals and Global Influences.

13 jun 2026, 22:51 UTC

Japan's Core Inflation Rate Expected to Hold at 1.4% Amid Cautious Market Sentiment and BOJ Policy Considerations

13 jun 2026, 22:41 UTC

Market anticipates June 15 release of NY Empire State Manufacturing Index at 13.2, signaling cautious optimism amid inflation concerns and geopolitical developments.

13 jun 2026, 22:41 UTC

Japan's Machinery Orders Expected to Rise 0.9% in April Amidst Mixed Economic Signals and Improving Investor Confidence

13 jun 2026, 22:41 UTC

Japan's Exports Expected to Rise 0.162% YoY in June Amid Positive Economic Sentiment and Geopolitical Easing, Despite Competition from China

13 jun 2026, 22:41 UTC

Mortgage Rates Set to Rise Amid Geopolitical Tensions and Economic Uncertainty, with Upcoming MBA Report Expected on June 17.

13 jun 2026, 22:32 UTC

UK Consumer Confidence Index for June 2026 Forecasted at -23 Amid Ongoing Inflation and Economic Uncertainty

13 jun 2026, 22:32 UTC

Canada's May 2026 Housing Starts Data Set for Release, Forecasted at 255K Units Amid Optimistic Market Sentiment and Government Initiatives.

13 jun 2026, 22:32 UTC

Brazil's Central Bank to Provide Key Interest Rate Insights on June 15, Amidst Cautious Market Sentiment and Global Economic Influences.

13 jun 2026, 22:32 UTC

Japan's trade deficit forecasted at -564.6 billion yen amid high import costs, but market optimism rises following easing U.S.-Iran tensions and strong Asian stock performance.

13 jun 2026, 22:32 UTC

Brazil's Retail Sales Report on June 16 Expected to Show Resilience Amid Mixed Economic Signals

Comparación entre iguales

Cambio de precio

Ocugen Inc previsión

Precio Objetivo

By TipRanks

699.17% repunte

Estimación a 12 Meses

Media 9.67 USD 699.17%

Máximo 12 USD

Mínimo 7 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ocugen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

Comprar

Mantener

Vender

De acuerdo con 6 analistas que ofrecen calificaciones bursátiles a para Ocugen Inc Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.